This article reviews recent studies of magnetic resonance imaging and magnetic resonance spectroscopy in demen tia, including Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, idiopathic Parkinson's disease, Huntington's disease, and vascular dementia. Magnetic resonance imaging and magnetic resonance spec troscopy can detect structural alteration and biochemical abnormalities in the brain of demented subjects and may help in the differential diagnosis and early detection of affected individuals, monitoring disease progression, and evaluation of therapeutic effect. (J Geriatr Psychiatry Neurol 2001; 14:145-166).
Get full access to this article
View all access options for this article.
References
1.
Wallin A.Current definition and classification of dementia diseases. Acta Neurol Scand1996; 168(Suppl):39-44.
2.
Morris JCClassification of dementia and Alzheimer's disease. Acta Neurol Scand1996; 165(Suppl):41-50.
3.
Geldmacher DS , Whitehouse Pj Jr. Differential diagnosis of Alzheimer's disease . Neurology1997; 48(Suppl 6):S2-S9.
Kaye JADiagnostic challenges in dementia. Neurology1998; 51(Suppl 1):S45-S52.
6.
Rosenstein LDDifferential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s. Neuropsychol Rev1998; 8:109-167.
7.
Lopez OL, Litvan I., Catt KE, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology1999; 53:1292-1299.
8.
Goulding Jmr , Signorini DF, Chatterjee S., et al. Inverse relation between Braak stage and cerebrovascular pathology in Alzheimer predominant dementia. J Neurol Neurosurg Psychiatry1999 ; 67:654-657.
9.
Pasquier F.Early diagnosis of dementia: neuropsychology. J Neurol1999; 246:6-15.
10.
Fleming KC, Adam AC, Petersen RCDementia: diagnosis and evaluation. Mayo Clin Proc1995; 70:1093-1107.
11.
Wahlund L-O.Magnetic resonance imaging and computed tomography in Alzheimer's disease. Acta Neurol Scand1996; 168(Suppl):50-53.
12.
Xanthakos S. , Krishnan KR, Kim DM, Charles HEMagnetic resonance imaging of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry1996; 20:597-626.
13.
Smith CDQuantitative computed tomography and magnetic resonance imaging in aging and Alzheimer's disease. J Neuroimaging1996; 6:44-53.
14.
Cousins JPClinical MR spectroscopy: fundamentals, current applications, and future potential . AJR Am J Roentgenol1995 ; 164:1337-1347.
15.
Ross BD, Bluml S., Cowan R., et al. In vivo MR spectroscopy of human dementia. Neuroimaging Clin NAm1998; 8:809-822.
16.
Pettegrew JW , Klunk WE, Panchalingam K., et al. Magnetic resonance spectroscopic changes in Alzheimer's disease . Ann N YAcad Sci1997 ; 826:282-306.
17.
Moore CM, Frederick BB, Renshaw PFBrain biochemistry using magnetic resonance spectroscopy: relevance to psychiatric illness in the elderly. J Geriatr Psychiatry Neurol1999; 12:107-117.
18.
Valenzuela MJ, Sachdev P.Magnetic resonance spectroscopy in AD. Neurology2001; 56:592-598.
19.
Kirsch SJ, Jacob RW, Butcher LL, Beatty J.Prolongation of magnetic resonance T2 time in hippocampus of human patients marks the presence and severity of Alzheimer's disease. Neurosci Lett1992; 134:187-190.
20.
Geula C.Abnormalities of neural circuitry in Alzheimer's disease : hippocampus and cortical cholinergic innervation. Neurology1998; 51(Suppl 1):S18-S29.
21.
Kidron D., Black SE, Stanchev P., et al. Quantitative MR volumetry in Alzheimer's disease: topographic markers and the effects of sex and education. Neurology1997; 49:1504-1512.
22.
Tanabe JL, Amend D., Schuff N., et al. Tissue segmentation of the brain in Alzheimer disease. AJNR Am J Neuroradiol1997; 18:115-123.
23.
Foundas AL, Eure KF, Seltzer B.Conventional MRI volumetric measures of parietal and insular cortex in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry1996; 20:1131-1144.
24.
Pantel J., Schroder J., Essig M., et al. Quantitative magnetic resonance imaging in geriatric depression and primary degenerative dementia. J Affect Disord1997; 42:69-83.
25.
Stout JC, Jernigan TL, Archibald SL, Salmon DPAssociation of dementia severity with cortical gray matter and abnormal white matter volumes in dementias of the Alzheimer type. Arch Neurol1996; 53:742-749.
26.
Brunetti A. , Postiglione A., Tedeschi E., et al. Measurement of global atrophy in Alzheimer's disease with unsupervised segmentation of spin-echo MRI studies. J Magn Reson Imaging2000; 11:260-266.
27.
Cahn DA, Sullivan EV, Shear PK, et al. Structural MRI correlates of recognition memory in Alzheimer's disease. J Int Neuropsychol Soc1998; 4:106-114.
28.
Fama R., Sullican EV, Shear PK, et al. Selective cortical and hippocampal volume correlates of Mattis dementia rating scale in Alzheimer disease. Arch Neurol1997; 54:719-728.
29.
Schofield PW , Logroscino G., Andrew HF, et al. An association between head circumference and Alzheimer's disease in a population-based study of aging and dementia . Neurology1997; 49:30-37.
30.
Graves AB, Mortimer JA, Larson EB, et al. Head circumference as a measure of cognitive reserve: association with severity of impairment in Alzheimer's disease. Br J Psychiatry1996; 169:86-92.
31.
Schofield PW , Mosesson RE, Stern Y., Mayeax R.The age at onset of Alzheimer's disease and an intracranial area measurement : a relationship . Arch Neurol1995; 52:95-98.
32.
Jenkins R., Fox NC, Rossor AM, et al. Intracranial volume and Alzheimer disease: evidence against the cerebral reserve hypothesis. Arch Neurol2000; 57:220-224.
33.
Mori E., Hirono N., Yamashita H., et al. Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease. Am J Psychiatry1997; 154:18-24.
34.
Deweer B., Lehericy S., Pillon B., et al. Memory disorders in probable Alzheimer's disease: the role of hippocampal atrophy as shown with MRI. J Neurol Neurosurg Psychiatry1995; 58:590-597.
35.
Yasuda M., Mori E., Kitagaki H., et al. Apolipoprotein E ∈4 allele and whole brain atrophy in late-onset Alzheimer's disease. Am J Psychiatry1998; 155:779-784.
36.
Frisoni GB, Beltramello A., Weiss C., et al. Linear measures of atrophy in mild Alzheimer disease. AJNR Am J Neuroradiol1996; 17:913-923.
37.
DeLeon MJ, George AE, Golomb J., et al. Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging1997; 18:1-11.
38.
Kohler S., Black SE, Sinden M., et al. Memory impairments associated with hippocampal versus parahippocampal-gyrus atrophy : an MR volumetry study in Alzheimer's disease. Neuropsychologia1998; 36:901-914.
39.
Laakso MP, Soininen H., Partanen K., et al. Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: correlation with memory functions . J Neural Transm1995; 9:73-86.
40.
Jack CR Jr, Petersen RC, O'Brien PC, Tangalos EGMRbased hippocampal volumetry in the diagnosis of Alzheimer's disease . Neurology1992; 42:183-188.
41.
Kesslak JP, Nalcioglu O., Cotman CWQuantification of magnetic resonance scan for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology1991; 41:51-54.
42.
Juottonen K. , Laakso MP, Partanen K., Soininen H.Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer's disease. AJNR Am J Neuroradiol1999; 20:139-144.
43.
Parnetti L. , Lowenthal DT, Presciutti O., et al. 1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease . JAm Geriatr Soc1996; 44:133-138.
44.
Lehericy S. , Baulac M., Chiras J., et al. Amygdalohippocampal MR volume measurements in the early stages ofAlzheimer disease. AJNR Am J Neuroradiol1994; 15:927-937.
45.
Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology1997; 49:786-794.
46.
Krasuski JS , Alexander GE, Horwitz B., et al. Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls). Biol Psychiatry1998; 43:60-68.
47.
Convit A., De Leon MJ, Tarshish C., et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol Aging1997 ; 18:131-138.
48.
Frisoni BF, Trabucchi M., Beltramello A.Hippocampal atrophy measurement in Alzheimer's disease. Int J Geriatr Psychiatry1996; 11:81-83.
49.
Horn R., Ostertum B., Fric M., et al. Atrophy of hippocampus in patients with Alzheimer's disease and other diseases with memory impairment. Dement Geriatr Cogn Disord1996; 7:182-186.
50.
Laakso MP, Soininen H., Partanen K., et al. MRI of the hippocampus in Alzheimer's disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol Aging1998; 19:23-31.
51.
Frisoni GB, Beltramello A., Weiss C., et al. Usefulness of simple measures of temporal lobe atrophy in probable Alzheimer's disease. Dementia1996; 7:15-22.
52.
Pucci E., Belardinelli N., Regnicolo L., et al. Hippocampus and parahippocampal gyrus linear measurements based on magnetic resonance in Alzheimer's disease. Eur Neurol1998; 39:16-25.
53.
Wahlund L-O. , Julin P., Lindqvist J., Scheltens P.Visual assessment of medial temporal lobe atrophy in demented and healthy controls: correlation with volumetry. Psychiatry Res1999; 90:193-199.
54.
Laakso MP, Partanen K., Lehtovirta M., et al. MRI of amygdala fails to diagnose early Alzheimer's disease . Neuroreport1995; 6:2414-2418.
55.
O'Brien JT, Desmond P., Ames D., et al. Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal aging, depression, vascular dementia and other causes of cognitive impairment. Psychol Med1997; 27:1267-1275.
56.
Bobinski M. , De Leon MJ, Wegiel J., et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience2000; 95:721-725.
57.
Squire LRMemory and the hippocampus: a synthesis from findings with rats, monkeys, and human. Psychol Rev1992; 99:195-231.
58.
Petersen RC , Jack CrJr, YC Xu, et al. Memory and MRI-based hippocampal volumes in aging and AD. Neurology2000; 54:581-587.
59.
Heun R., Mazanek M., Atzor KR, et al. Amygdala-hippocampal atrophy and memory performance in dementia of Alzheimer type. Dement Geriatr Cogn Disord1997; 8:329-336.
60.
Wilson RS, Sullivan M., de Toledo-Morrell L., et al. Association of memory and cognition in Alzheimer's disease with volumetric estimates of temporal lobe structures. Neuropsychology1996; 10:459-463.
61.
Mori E., Yoneda Y., Yamashita H., et al. Medial temporal structures related to memory impairment in Alzheimer's disease: an MRI volumetric study. J Neurol Neurosurg Psychiatry1997; 63:214-221.
62.
Geroldi C., Pihlajamaki M., Laakso MP, et al. Apo E-e4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology1999; 53:1825-1832.
63.
Tanaka S., Kawamata J., Shimohama S., et al. Inferior temporal lobe atrophy and APOE genotypes in Alzheimer's disease: x-ray computed tomography, magnetic resonance imaging and Xe-133 SPECT studies. Dement Geriatr Cogn Disord1998; 9:90-98.
64.
Lehtovirta M., Laakso MP, Soininen H., et al. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes . Neuroscience1995; 67:65-72.
65.
Plassman BL , Welsh-Bohmer KA, Bigler ED, et al. Apolipoprotein E ∈4 allele and hippocampal volume in twins with normal cognition. Neurology1997; 48:985-989.
66.
Tohgi H., Takahashi S., Kato E., et al. Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E ∈4 allele. Neurosci Lett1997; 236:21-24.
67.
Reiman EM, Uecker A., Caselli RJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol1998 ; 44:288-291.
68.
Soininen H. , Partanen K., Pitkanen A., et al. Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ∈4 allele. Neurology1995; 45:391.
69.
Lehtovirta M., Soininen H., Laakso MP, et al. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E ∈4 allele . J Neurol Neurosurg Psychiatry1996; 60:644-649.
70.
Geroldi C., Laakso MP, DeCarli C., et al. Apolipoprotem E genotype and hippocampal asymmetry in Alzheimer's disease : a volumetric MRI study. J Neurol Neurosurg Psychiatry2000; 68:93-96.
71.
Jack CR Jr, Petersen RC, Xu YC, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol1998; 43:303-310.
72.
Barber R., Golkar A., Scheltens P., et al. Apolipoprotein E epsilon 4 allele, temporal lobe atrophy, and white matter lesions in late life dementias. Arch Neurol1999; 56:961-965.
73.
Lehtovirta M., Laakso MP, Frisoni GB, Soininen H.How does the apolipoprotein E genotype modulate the brain in aging and in Alzheimer's disease ? A review of neuroimaging studies. Neurobiol Aging2000; 21:293-300.
74.
Scott SA, Dekosky ST, Sparks DL, et al. Amygdala cell loss and atrophy in Alzheimer's disease. Ann Neurol1992; 32:555-563.
75.
Bobinski M. , Wegiel J., Wisniewski HM, et al. Neurofibrillary pathology-correlation with hippocampal formation atrophy in Alzheimer's disease . Neurobiol Aging1996; 17:909-919.
76.
Bobinski M. , Wegiel J., Wisniewski HM, et al. Atrophy of hippocampal formation subdivisions correlates with stages and duration of Alzheimer disease . Dementia1995; 6:205-210.
77.
Bobinski M. , Wegiel J., Tarnawski M., et al. Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol1997; 56:414-420.
78.
Hyman BT, Van Hoesen GW, Damasio AR, Barnes CLAlzheimer's disease: cell-specific pathology isolates the hippocampal formation . Science1984; 225:1168-1170.
79.
Juottonen K. , Laakso MP, Insausti R., et al. Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease. Neurobiol Aging1998; 19:15-22.
80.
Bobinski M. , DeLeon MJ, Convit A., et al. MRI of entorhinal cortex in mild Alzheimer's disease. Lancet1999; 353:38-40.
81.
Xu Y., Jack CR Jr, O'Brien PC, et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology2000; 54:1760-1767.
82.
Killiany RJ , Gomez-Isla T., Moss M., et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol2000; 47:430-439.
83.
Juottonen K. , Lehtovirta M., Helisalmi S., et al. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E ∈4 allele. J Neurol Neurosurg Psychiatry1998; 65:322-327.
84.
Lyoo IK, Satlin A., Lee CK, Renshaw PFRegional atrophy of the corpus callosum in subjects with Alzheimer's disease and multi-infarct dementia. Psychiatry Res1997; 74:63-72.
85.
Pantel J., Schroder J., Jauss M., et al. Topography of callosal atrophy reflects distribution of regional cerebral volume reduction in Alzheimer's disease. Psychiatry Res1999; 90:181-192. 86. Janowsky JS, Kaye JA, Carper RAAtrophy of the corpus callosum in Alzheimer's disease versus healthy aging . J Am Geriatr Soc1996; 44:798-803.
86.
Hampel H., Teipel S., Alexander GE, et al. Corpus callosum atrophy is a possible indicator of region- and cell type-specific neuronal degeneration in Alzheimer disease. Arch Neurol1998; 55:193-198.
87.
Teipel SJ, Hampel H., Alexander GE, et al. Dissociation between corpus callosum atrophy and white matter pathology in Alzheimer's disease. Neurology1998; 51:1381-1385.
88.
Vermersch P. , Roche J., Hamon M., et al. White matter magnetic resonance imaging hyperintensity in Alzheimer's disease: correlation with corpus callosum atrophy . J Neurol1996 ; 243:231-234.
89.
Rossor MN, Fox NC, Freeborough PA, Roques PKSlowing the progression of Alzheimer disease: monitoring progression . Alzheimer Dis Assoc Disord1997; 11(Suppl 5):S6-S9.
90.
Fox NC, Freeborough PA, Rossor MNVisualization and quantification of rates of atrophy in Alzheimer's disease . Lancet1996; 348:94-97.
91.
Fox NC, Freeborough PABrain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imag1997; 7:1069-1075.
92.
Fox NC, Warrington EK, Rossor MNSerial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet1999; 353:2125.
93.
Fox NC, Cousens S., Scahill R., et al. Serial registered brain MRI to measure disease progression in Alzheimer's disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol2000; 57:339-344.
94.
Fox NC, Scahill RI, Crum WR, Rossor MNCorrelation between rates of brain atrophy and cognitive decline in Alzheimer's disease. Neurology1999; 52:1687-1689.
95.
Jack CR Jr, Petersen RC, Xu Y., et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology1998; 51:993-999.
96.
Fox NC, Warrington EK, Freeborough PA, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease: a longitudinal MRI study. Brain1996; 119:2001-2007.
97.
Kaye JA, Swihart T., Howieson D., et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology1997; 48:1297-1304.
98.
Laakso MP, Lehtovirta M., Partanen K., et al. Hippocampus in Alzheimer's disease: a 3-year follow-up MRI study . Biol Psychiatry2000; 47:557-561.
99.
Jack CR Jr, Petersen RC, Xu Y., et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology2000; 55:484-489.
100.
Wahlund L-O. , Julin P., Lannfelt L., et al. Inheritance of the ApoE ∈4 allele increases the rate of brain atrophy in dementia patients. Dement Geriatr Cogn Disord1999 ; 10:262-268.
101.
Yamaguchi S., Nakagawa T., Arai H., Sasaki H.Temporal progression of hippocampal atrophy and apolipoprotein E gene in Alzheimer's disease. J Am Geriatr Soc1996; 44:216-217.
102.
O'Brien JT , Ames D., Schwietzer I.White matter changes in depression and Alzheimer's disease: a review of magnetic resonance imaging studies. Int J Geriatr Psychiatry1996; 11:681-694.
103.
Scheltens P., Barkhof F., Leys D., et al. Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology1995; 45:883-888.
104.
Yamaji S., Ishii K., Masahiro S., et al. Changes in cerebral blood flow and oxygen metabolism related to magnetic resonance imaging white matter hyperintensities in Alzheimer's disease. J Nucl Med1997; 38:1471-1474.
105.
Fazekas F. , Kapeller P., Schmidt R., et al. The relation of cerebral magnetic resonance signal hyperintensities to Alzheimer's disease . J Neurol Sci1996; 142:121-125.
106.
Smith CD, Snowdon DA, Wang H., Markesbery WRWhite matter volumes and periventricular white matter hyperintensities in aging and dementia. Neurology2000; 54:838-842. 108. Azher SN, Doody RS, Haykal HA, et al. Does Apo ∈4 correlate with MRI changes in Alzheimer's disease? Neurology1999; 52(Suppl 2):A366.
107.
Amar K., Macgowan S., Wilcock G., et al. Are genetic factors important in the aetiology of leukoaraiosis? Results from a memory clinic population. Int J Geriatr Psychiatry1998; 13:585-590.
108.
Hirono N., Yasuda M., Tanimukai S., et al. Effect of the apolipoprotein E ∈4 allele on white matter hyperintensities in dementia. Stroke2000; 31:1263-1268.
109.
Sawada H., Udaka F., Izumi Y., et al. Cerebral white matter lesions are not associated with apoE genotype but with age and female sex in Alzheimer's disease. JNeurol Neurosurg Psychiatry2000; 68:653-656.
110.
Bronge L., Fernaeus S-E, Blomberg M., et al. White matter lesions in Alzheimer's patients are influenced by apolipoprotein E genotype. Dement Geriatr Cogn Disord1999; 10:89-96.
111.
Fazekas F. , Chawlug JB, Alavi A., et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol1987; 149:351-356.
112.
Laakso MP, Partanen K., Soininen H., et al. MR T2 relaxometry in Alzheimer's disease and age-associated memory impairment. Neurobiol Aging1996; 17:535-540.
113.
Pitkanen A. , Laakso M., Kalviainen R., et al. Severity of hippocampal atrophy correlates with the prolongation of MRI T2 relaxation time in temporal lobe epilepsy but not in Alzheimer's disease. Neurology1996; 46:1724-1730.
114.
Hanyu H., Sakurai H., Iwamoto T., et al. Diffusion-weighted MR imaging of the hippocampus and temporal white matter in Alzheimer's disease. J Neurol Sci1998; 156:195-200.
115.
Hanyu H., Shindo H., Kakizaki D., et al. Increased water diffusion in cerebral white matter in Alzheimer's disease. Gerontology1997; 43:343-351.
116.
Sandson TA , Felician O., Edelman RR, Warach S.Diffusion-weighted magnetic resonance imaging in Alzheimer's disease. Dement Geriatr Cogn Disord1999; 10:166-171.
117.
Hanyu H., Imon Y., Sakurai H., et al. Regional differences in diffusion abnormality in cerebral white matter lesions in patients with vascular dementia of the Binswanger type and Alzheimer's disease. Eur J Neurol1999; 6:195-203.
118.
Postiglione A., Lassen NA, Holman BLCerebral blood flow in patients with dementia of Alzheimer's type. Aging Clin Exp Res1993 ; 5:19-26.
119.
Gonzalez RG , Fischman AJ, Guimaraes AR, et al. Functional MR in the evaluation of dementia: correlation of abnormal dynamic cerebral blood volume measurements with changes in cerebral metabolism on positron emission tomography with fludeoxyglucose F 18. AJNR Am J Neuroradiol1995; 16:1763-1770.
120.
Harris GJ, Lewis RF, Satlin A., et al. Dynamic susceptibility contrast MRI of regional cerebral blood volume in Alzheimer's disease. Am J Psychiatry1996; 153:721-724.
121.
Levin JM, Ross MH, Harris G., Renshaw PFApplications of dynamic susceptibility contrast magnetic resonance imaging in neuropsychiatry. Neuroimage1996 ; 4(Suppl):S147-S162.
122.
Johnson KA , Renshaw PF, Becker JA, et al. Comparison of functional MRI and SPECT in Alzheimer's disease. Neurology1995; 45(Suppl):874.
123.
Mass LC, Harris GJ, Satlin A., et al. Regional cerebral blood volume measured by dynamic susceptibility contrast MR imaging in Alzheimer's disease: a principal components analysis . J Magn Reson Imaging1997; 7:215-219.
124.
Harris GJ, Lewis RF, Satlin A., et al. Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine . AJNR Am J Neuroradiol1998; 19:1727-1732.
125.
Alsop DC, Detre JA, Grossman M.Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol2000 ; 47:93-100.
126.
Sandson TA , O'Connor M., Sperling RA, et al. Noninvasive perfusion MRI in Alzheimer's disease: a preliminary report. Neurology1996 ; 47:1339-1342.
127.
Flicker C. , Ferris SH, Reisberg B.Mild cognitive impairment in the elderly: predictors of dementia. Neurology1991; 41:1006-1009.
128.
Ritchie K. , Touchon J.Mild cognitive impairment: conceptual basis and current nosological status. Lancet2000 ; 355:225-228.
129.
Convit A., De Leon MJ, Tarshish C., et al. Hippocampal volume losses in minimally impaired elderly. Lancet1995; 345:266. 132. Jack CRJr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology1999; 52:1397-1403.
130.
Brun A., Englund B., Gustafson L., et al. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester groups. J Neurol Neurosurg Psychiatry1994; 57:416-418.
131.
Mann DM, South PWThe topographic distribution of brain atrophy in frontal lobe dementia . Acta Neuropathol1993; 85:334-340.
132.
Liu X., Passant U., Risberg J., et al. Synapse density related to cerebral blood flow and symptomatology in frontal lobe degeneration and Alzheimer's disease. Dement Geriatr Cogn Disord1999; 10(Suppl 1):63-70.
133.
Frisoni GB, Beltramello A., Geroldi C., et al. Brain atrophy in frontotemporal dementia. J Neurol Neurosurg Psychiatry1996; 61:157-165.
134.
Edward-Lee T., Miller BL, Benson DF, et al. The temporal variant of frontotemporal dementia. Brain1997; 120:1027-1040.
135.
Kitagaki H. , Mori E., Yamaji S., et al. Frontotemporal dementia and Alzheimer disease: evaluation of cortical atrophy with automated hemispheric surface display generated with MR images. Radiology1998; 208:431-439.
136.
Miller BL, Gearhart R.Neuroimaging in the diagnosis of frontotemporal dementia. Dement Geriatr Cogn Disord1999; 10(Suppl 1):71-74.
137.
Duara R., Barker W., Luis CAFrontotemporal dementia and Alzheimer's disease: differential diagnosis. Dement Geriatr Cogn Disord1999; 10(Suppl 1):37-42.
138.
Perry RJ, Hodges JRDifferentiating frontal and temporal variant frontotemporal dementia from Alzheimer's disease. Neurology2000; 54:2277-2284.
139.
Fukui T., Kertesz A.Volumetric study of lobar atrophy in Pick complex and Alzheimer's disease . J Neurol Sci2000; 174:111-121.
140.
Frisoni GB , Laakso MP, Beltramello A., et al. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease . Neurology1999; 52:91-100.
141.
Lavenu I., Pasquier F., Lebert F., et al. Explicit memory in frontotemporal dementia: the role of medial temporal atrophy. Dement Geriatr Cogn Disord1998; 9:99-102.
142.
Laakso MP, Frisoni GB, Kononen M., et al. Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer's disease: a morphometric MRI study. Biol Psychiatry2000; 47:1056-1063.
143.
Kaufer DI, Miller BL, Itti L., et al. Midline cerebral morphometry distinguishes frontotemporal dementia and Alzheimer's disease. Neurology1997; 48:978-985.
144.
Kitagaki H. , Mori E., Hirono N., et al. Alteration of white matter MR signal intensity in frontotemporal dementia. AJNR Am J Neuroradiol1997; 18:367-378.
145.
Papka M., Rubio A., Schiffer RBA review of Lewy body disease, an emerging concept of cortical dementia . J Neuropsychiatry Clin Neurosci1998; 10:267-279.
146.
Kalra S., Bergeron C., LangAE. Lewy body disease and dementia : a review. Arch Intern Med1996; 156:487-493.
147.
McKeith LG , Galasko D., Kosaka K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996; 47:1113-1124.
148.
Gomez-Tortosa E., Newell K., Irizarry MC, et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology1999; 53:1284-1291.
149.
Gomez-Isla T., Growdon WB, McNamara M., et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology1999; 53:2003-2009.
150.
Hashimoto M., Kitagaki H., Imamura T., et al. Medial temporal and whole-brain atrophy in dementia with Lewy bodies: a volumetric MRI study . Neurology1998; 51:357-362.
151.
Double KL, Halliday GM, McRitchie DA, et al. Regional brain atrophy in idiopathic Parkinson's disease and diffuse Lewy body disease. Dementia1996; 7:304-313.
152.
Harvey GT, Hughes J., McKeith IG, et al. Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study. Psychol Med1999; 29:181-187.
153.
Cordato NJ , Halliday GM, Harding AJ, et al. Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann Neurol2000; 47:718-728.
154.
Barber R., Gholkar A., Schelten P., et al. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies . Neurology1999; 52:1153-1158.
155.
Barber R., Ballard C., McKeith IG, et al. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology2000 ; 54:1304-1309.
156.
Lippa CF, Smith TW, Swearer JMAlzheimer's disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol1994; 35:81-88.
157.
Lippa CF, Johnson R., Smith TWThe medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease. Ann Neurol1998; 43:102-106.
158.
Schmidt ML , Martin JA, Lee Vmy, Trojanowski JQConvergence of Lewy bodies and neurofibrillary tangles in amygdala neuron of Alzheimer's disease and Lewy body disorders . Acta Neuropathol1996; 91:475-481.
159.
O'Brien JT , Harvey G., Hughes J., et al. Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease . Neurobiol Aging1998; 19(Suppl 2):A862.
160.
Barber R., Scheltens P., Gholkar A., et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging . J Neurol Neurosurg Psychiatry1999; 67:66-72.
161.
Mayeux R., Denaro J., Hemenegildo N., et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol1992; 49:492-497.
162.
Mahler ME, Cummings JLAlzheimer disease and the dementia of Parkinson disease: comparative investigations . Alzheimer Dis Assoc Disord1990; 4:133-149.
163.
Bartzokis G., Cummings JL, Markham CH, et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects . Magn Reson Imaging1999; 17:213-222.
164.
Dexter DT, Carayon A., Javoy-Agid F., et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting basal ganglia. Brain1991; 114:1953-1975.
165.
Mann VM, Cooper JM, Daniel SE, et al. Complex I, iron and ferritin in Parkinson's disease substantia nigra. Ann Neurol1994; 36:876-881.
166.
Chen JC, Hardy PA, Kucharczyk W., et al. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol1993; 14:275-281.
167.
Olanow CWMagnetic resonance imaging in parkinsonism. Neurol Clin1992; 10:405-420.
168.
Ryvlin P., Broussolle E., Piollet H., et al. Magnetic resonance imaging evidence of decreased putaminal iron content in idiopathic Parkinson's disease. Arch Neurol1995; 52:583-588.
169.
Antonini A. , Leenders KL, Meier D., et al. T2 relaxation time in patients with Parkinson's disease. Neurology1993; 43:697-700.
170.
Gorell JM, Ordidge RJ, Brown GG, et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology1995; 45:1138-1143.
Aichner F., Wagner M., Kremser CH, Felber S.MR-imaging of non-Alzheimer's dementia. J Neural Transm1996; 47(Suppl):143-153.
173.
Braffman BH, Grossman RI, Goldberg HI, et al. MR imaging of Parkinson disease with spin-echo and gradient-echo sequences. AJR Am J Roentgenol1989; 152:159-165.
174.
Duguid JR, De La Paz R., De Groot J.Magnetic resonance imaging of the midbrain in Parkinson's disease . Ann Neurol1986; 20:744-747.
175.
Stern MB, Braffman BH, Skolnick BE, et al. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology1989; 39:1524-1526.
176.
Schwarz J. , Kraft E., Vogl T., et al. Relative quantification of signal on T2-weighted images in the basal ganglia: limited value in differential diagnosis of patients with parkinsonism. Neuroradiology1999; 41:124-128.
177.
Lisanby SH , McDonald WM, Massey EW, et al. Diminished subcortical nuclei volumes in Parkinson's disease by MR imaging. J Neural Transm1993; 40(Suppl):13-21.
178.
Laakso MP, Partanen K., Riekkinen P. Jr, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study . Neurology1996; 46:678-681.
179.
Bancher C. , Braak H., Fischer P., Jellinger KANeuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett1993; 162:179-182.
180.
Schulz JB, Skalej M., Wedekind D., et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol1999; 45:65-74.
181.
Clarfield AMThe reversible dementias: do they reverse ? Ann Intern Med1988; 109:476-486.
182.
Wardlaw JM , Sellar RJEarly caudate nucleus atrophy in Huntington's disease: does it correlate with presenting symptoms ? Neuroradiology1991; 33:238-240.
183.
Brandt J., Bylsma FW, Aylward EH, et al. Impaired source memory in Huntington's disease and its relation to basal ganglia atrophy. J Clin Exp Neuropsychol1995; 17:868-877.
184.
Ginovart N. , Lundin A., Farde L., et al. PET study of pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease . Brain1997; 120:501-514.
185.
Harris GJ, Aylward EH, Peyser CE, et al. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch Neurol1996; 53:316-324.
186.
Aylward EH , Schwartz J., Machlin S., Pearlson G.Bicaudate ratio as a measure of caudate volume on MR images. AJNR Am J Neuroradiol1991; 12:1217-1222.
187.
Backman L. , Robins-Wahlin T-B., Lundin A., et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain1997; 120:2207-2217.
188.
Starkstein SE, Brandt J., Bylsma F., et al. Neuropsychological correlations of brain atrophy in Huntington's disease: a magnetic resonance imaging study . Neuroradiology1992; 34:487-489.
189.
Harris GJ, Pearlson GD, Peyser CE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann Neurol1992; 31:69-75.
190.
Jernigan TL , Salmon DP, Butters N., Hesselink JRCerebral structure on MRI, part II: specific changes in Alzheimer's and Huntington's disease . Biol Psychiatry1991; 29:68-81.
191.
Aylward EH , Anderson NB, Bylsma FW, et al. Frontal lobe volume in patients with Huntington's disease. Neurology1998; 50:252-258.
192.
Aylward EH , Li Q., Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology1997; 48:394-399.
193.
Aylward EH , Brandt J., Codori A., et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology1994; 44:823-828.
194.
Aylward EH , Codori AM, Barta PE, et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington's disease. Arch Neurol1996; 53:1293-1296.
195.
Harris GJ, Codori AM, Lewis RF, et al. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain1999; 122:1667-1678.
196.
Savoiardo M., Strada L., Oliva D., et al. Abnormal MRI signal in the rigid form of Huntington's disease. J Neurol Neurosurg Psychiatry1991; 54:888-891.
197.
Kido DK, Shoulson I., Manzione JV Jr, Harnish P.High field strength MRI scans in patients with Huntington's disease. AJNR Am J Neuroradiol1987; 8:934.
198.
Rutledge JN , Hilal SK, Silver AJ, et al. Study of movement disorders and brain iron by MR. AJNR Am JNeuroradiol1987; 8:397-411.
199.
Chui HCDementia: a review emphasizing clinicopathologic correlation and brain-behavior relationships. Arch Neurol1989; 46:806-814.
200.
Chui HC, Victoroff JI, Margolin D., et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers . Neurology1992; 42:473-480.
201.
American Psychiatric Association.Diagnosis and statistical manual of mental disorders. 3rd Ed. Washington, DC: APA, 1980.
202.
Hachinski VC, Iliff LD, Zlihka E., et al. Cerebral blood flow in dementia. Arch Neurol1975; 32:632-637.
203.
Roman GC, Tatemichi TK, Erkinjuntti T., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology1993; 43:250-260.
204.
Victoroff J., Mack WJ, Lyness S., Chui HCMulticenter clinicopathological correlation in dementia. Am J Psychiatry1995 ; 152:1476-1484.
205.
Longstreth WT, Bernick C., Manolio TA, et al, for the Cardiovascular Health Study Collaborative Research Group. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people. Arch Neurol1998; 55:1217-1225.
206.
Giubilei F. , Bastianello S., Paolillo A., et al. Quantitative magnetic resonance analysis in vascular dementia. JNeurol1997; 244:246-251.
207.
Pantel J., Schroder J., Essig M., et al. In vivo quantification of brain volumes in subcortical vascular dementia and Alzheimer's disease: an MRI-based study. Dement Geriatr Cogn Disord1998; 9:309-316.
208.
Hershey LA , Modic MT, Greenough PG, Jaffe DFMagnetic resonance imaging in vascular dementia . Neurology1987 ; 37:29-36.
209.
Liu CK, Miller BL, Cummings JL, et al. A quantitative MRI study of vascular dementia. Neurology1992; 42:138-143.
210.
Schmidt R.Comparison of magnetic resonance imaging in Alzheimer's disease, vascular dementia and normal aging. Eur Neurol1992; 32:164-169.
211.
MacKay S., Meyerhoff DJ, Constans JM, et al. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol1996; 53:167-174.
212.
Olsson Y., Brun A., Englund E.Fundamental pathological lesions in vascular dementia. Acta Neurol Scand1996; 168 (Suppl):31-38.
213.
Yamauchi H., Fukuyama H., Ogawa M., et al. Callosal atrophy in patients with lacunar infarction and extensive leukoariosis : an indicator of cognitive impairment. Stroke1994; 9:1788-1793.
214.
Yamanouchi H. , Sugiura S., Shimada H.Loss of nerve fibers in the corpus callosum of progressive subcortical vascular encephalopathyJ Neurol1990; 237:39-41.
215.
Corbett A., Bennett H., Kos S.Cognitive dysfunction following subcortical infarction. Arch Neurol1994; 51:999-1007.
216.
Erkinjuntti T., Benavente D., Eliasziw M., et al. Diffuse vacuolization (spongiosis) and arteriolosclerosis in the frontal white matter occurs in vascular dementia . Arch Neurol1996; 53:325-332.
217.
Fukuda H., Kobayashi S., Okada K., Tsunematsu T.Frontal white matter lesions and dementia in lacunar infarction. Stroke1990; 21:1143-1149.
218.
Charletta D., Gorelick PB, Dollear TJ, et al. CT and MRI findings among African-Americans with Alzheimer's disease, vascular dementia, and stroke without dementia. Neurology1995; 45:1456-1461.
219.
Sultzer DL , Mahler ME, Cummings JL, et al. Cortical abnormalities associated with subcortical lesions in vascular dementia : clinical and positron emission tomographic findings. Arch Neurol1995; 52:773-780.
220.
Sabri O., Ringelstein E-B., Hellwig D., et al. Neuropsychological impairment correlates with hypoperfusion and hypometabolism but not with severity of white matter lesions on MRI in patients with cerebral microangiopathy. Stroke1999; 30:556-566.
221.
Gass A., Oster M., Cohen S., et al. Assessment of T2- and T1-weighted MRI brain lesion load in patients with subcortical vascular encephalopathy. Neuroradiology1998; 40:503-506.
222.
Tohgi H., Yonezawa H., Takahashi S., et al. Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes. Neuroradiology1998; 40:131-137.
223.
Choi SH, Na DL, Chung CS, et al. Diffusion-weighted MRI in vascular dementia. Neurology2000; 54:83-89.
224.
Tanabe JL, Ezekiel F., Jagust WL, et al. Magnetization transfer ratio of white matter hyperintensities in subcortical ischemic vascular dementia. AJNR Am J Neuroradiol1999; 20:839-844.
225.
Sullivan P. , Pary R., Telang F., et al. Risk factors for white matter changes detected by magnetic resonance imaging in the elderly. Stroke1990; 21:1424-1428.
226.
Obara K., Meyer JS, Muramatsu K., Mortel KFLacune-associated cerebral hypoperfusion correlates with cognitive testing . J Stroke Cerebrovasc Dis1994; 4:121-129.
227.
Castillo M. , Kwock L., Mukherji SKClinical applications of proton MR spectroscopy . AJNR Am J Neuroradiol1996; 17:1-15.
228.
Koller KJ, Zaczek R., Coyle JTN-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem1984; 43:1136-1142.
229.
Blakely RD , Coyle JTThe neurobiology of N-acetylaspartylglutamate . Int Rev Neurobiol1988; 30:39-100.
230.
Birken DL, Oldendorf WHN-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev1989; 13:23-31.
231.
Urenjak J. , Williams SR, Gadian DG, Noble M.Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci1993; 13:981-989.
232.
Miller BLA review of chemical issues in H1 NMR spectroscopy : N-acetyl-L aspartate, creatine and choline. NMR Biomed1991; 4:47-52.
233.
Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesion. Brain1994; 117:49-58.
234.
De Stefano N., Matthews PM, Arnold DLReversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med1995 ; 34:721-727.
235.
Cendes F., Andermann F., Dubeau F., et al. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy: evidence from proton MR spectroscopic imaging . Neurology1997; 49:1525-1533.
236.
Kalra S., Cashman NR, Genge A., Arnold DLRecovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport1998; 9:1757-1761.
237.
Ernst T., Chang L., Melchor R., Mehringer CMFrontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology1997; 203:829-836.
238.
Parnetti L. , Tarducci R., Presciutti O., et al. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging . Mechan Aging Dev1997; 97:9-14.
239.
Rose SE, De Zubicaray GI, Wang D., et al. A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging1999; 17:291-299.
240.
Miller BL, Moats RA, Shonk T., et al. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology1993 ; 187:433-437.
241.
Moats RA, Ernst T., Shonk TK, Ross BDAbnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med1994; 32:110-115.
242.
Shonk TK, Moats RA, Gifford P., et al. Probable Alzheimer disease : diagnosis with proton MR spectroscopy . Radiology1995; 195:65-72.
243.
Heun R., Schlegel S., Graf-Morgenstern M., et al. Proton magnetic resonance spectroscopy in dementia of Alzheimer type. Int J Geriatr Psychiatry1997; 12:349-358.
244.
Kattapong VJ, Brooks WM, Wesley MH, et al. Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch Neurol1996; 53:678-680.
245.
Klunk WE, Panchalingam K., Moossy J., et al. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study. Neurology1992; 42:1578-1585.
246.
Huang W., Alexander GE, Daly EM, et al. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. Am J Psychiatry1999; 156:1879-1886.
247.
Pfefferbaum A., Adalsteinsson E., Spielman D., et al. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease . Arch Gen Psychiatry1999; 56:185-192.
248.
Mohanakrishnan P., Fowler AH, Vonsattel JP, et al. Regional metabolic alterations in Alzheimer's disease: an in vitro 1H NMR study of the hippocampus and cerebellum . J Gerontol1997; 52:B111-B117.
249.
Schuff N., Amend D., Ezekiel F., et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease: a proton MR spectroscopic imaging and MRI study. Neurology1997; 49:1513-1521.
250.
Tedeschi G. , Bertolino A., Lundbom N., et al. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology1996; 47:696-704.
251.
MacKay S., Ezekiel F., Di Sclafani V., et al. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology1996; 198:537-545.
252.
Meyerhoff DJ , MacKay S., Constans JM, et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol1994; 36.40-47.
253.
Constans JM, Meyerhoff DJ, Gerson J., et al. H-1 MR spectroscopic imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia. Radiology1995; 197:517-523.
254.
Schuff N., Amend DL, Meyerhoff DJ, et al. Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology1998; 207:91-102.
255.
Lazeyras F. , Charles HC, Tupler LA, et al. Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy . Psychiatry Res1998; 82:95-106.
256.
Klunk WE, Xu C., Panchalingam K., et al. Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol Aging1996; 17:349-357.
257.
Brown GG, Garcia JH, Gdowski JW, et al. Altered brain energy metabolism in demented patients with multiple subcortical ischemic lesions: working hypotheses. Arch Neurol1993; 50:384-388.
258.
Kwo-On-Yuen PF, Newmark RD, Budinger TF, et al. Brain N-acetyl-L-aspartic acid in Alzheimer's disease: a proton magnetic resonance spectroscopy study . Brain Res1994; 667:167-174.
259.
Mohanakrishnan P., Fowler AH, Vonsattel JP, et al. An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp Brain Res1995; 102:503-510.
260.
Nitsch RM, Blusztajn JK, Pittas AG, et al. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A1992; 89:1671-1675.
261.
Nitsch R., Pittas A., Blusztajn JK, et al. Alterations of phospholipid metabolites in postmortem brain from patients with Alzheimer's disease. Ann N Y Acad Sci1991; 640:110-113.
262.
Ross BDBiochemical considerations in H1 spectroscopy: glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed1991; 4:59-63.
263.
Frahm J., Bruhn H., Gyngell ML, et al. Localized high-resolution H-1 NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med1989; 9:79-93.
264.
Brown TR, Kincaid BM, Ugurbil K.NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci U S A1982; 79:3523-3526.
265.
Duijn JH, Matson GB, Maudsley AA, Weiner MW3D phase encoding 1H spectroscopic imaging of human brain. Magn Reson Imaging1992; 10:315-319.
266.
Maudsley AA , Lin E., Weiner MWSpectroscopic imaging display and analysis . Magn Reson Imaging1992; 10:471-485.
267.
Shiino A., Matsuda M., Morikawa S., et al. Proton magnetic resonance spectroscopy with dementia. Surg Neurol1993; 39:143-147.
268.
Christiansen P., Schlosser A., Henriksen O.Reduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease. Magn Reson Imaging1995; 13:457-462.
269.
Schechter R., Yen S-HC , Terry RDFibrous astrocytes in senile dementia of the Alzheimer type. J Neuropathol Exp Neurol1981 ; 40:95-101.
270.
Jessen F., Block W., Traber F., et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology2000; 55:684-688.
271.
Kantarci K. , Jack CR Jr, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology2000; 55:210-217.
272.
Terry RD, Peck A., DeTeresa R., et al. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol1981; 10:184-192.
273.
Doraiswamy PM, Charles HC, Krishnan KRPrediction of cognitive decline in early Alzheimer's disease. Lancet1998; 352:1678.
274.
SatlinA., Bodick N., Offen WW, Renshaw PFBrain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist . Am J Psychiatry1997; 154:1459-1461.
275.
Smith CD, Gallenstein LG, Layton WJ, et al. 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease. Neurobiol Aging1993; 14:85-92.
276.
Pettegrew JW, Moossy J., Withers G., et al. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J Neuropathol Exp Neurol1988; 47:235-248.
277.
Cuénod CA, Kaplan DB, Michot JL, et al. Phospholipid abnormalities in early Alzheimer's disease: in vivo phosphorus 31 magnetic resonance spectroscopy. Arch Neurol1995; 52:89-94.
278.
Pettegrew JW, Withers G., Panchalingam K., Post JF31P nuclear magnetic resonance (NMR) spectroscopy of brain in aging and Alzheimer's disease. J Neural Transm1987; 24(Suppl):261-268.
Pettegrew JW, Panchalingam K., Moossy J., et al. Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease. Arch Neurol1988; 45:1093-1096.
281.
McClure RJ , Kanfer JN, Panchalingam K., et al. Magnetic resonance spectroscopy and its application to aging and Alzheimer's disease. Neuroimaging Clin NAm1995; 5:69-86.
282.
Pettegrew JW, Panchalingam K., Klunk WE, et al. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study . Neurobiol Aging1994; 15:117-132.
283.
Pettegrew JW, Klunk WE, Panchalingam K., et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging1995; 16:1-4.
284.
Gonzalez RG , Guimaraes AR, Moore GJ, et al. Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease. Alzheimer Dis Assoc Disord1996; 10:46-52.
285.
Murphy DG, Bottomley PA, Salerno JA, et al. An in vivo study of phosphorus and glucose metabolism in Alzheimer's disease using magnetic resonance spectroscopy and PET. Arch Gen Psychiatry1993; 50:341-349.
286.
Bottomley PA, Cousins JP, Pendrey DL, et al. Alzheimer dementia: quantification of energy metabolism and mobile phosphoesters with P-31 NMR spectroscopy. Radiology1992; 183:695-699.
287.
Smith CD, Pettigrew LC, Avison MJ, et al. Frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease. Ann Neurol1995; 38:194-201.
288.
Cohen BM, Renshaw PF, Stoll AL, et al. Decreased brain choline uptake in older adults: an in vivo proton magnetic resonance spectroscopy study. JAMA1995; 274:902-907.
289.
Brown GG, Levin SR, Gorell JM, et al. In vivo 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology1989 ; 39:1423-1427.
290.
Chen YI, Jenkins BG, Fink S., Rosen BREvidence for impairment of energy metabolism in Parkinson's disease using invivo localized MR spectroscopy. Proc Soc Magn Reson1994; 1:194.
291.
Hu MT, Taylor-Robinson SD, Chaudhuri KR, et al. Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. J Neurol Neurosurg Psychiatry1999; 67:20-26.
292.
Choe BY, Park JW, Lee KS, et al. Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invest Radiol1998; 33:450-455.
293.
Holshouser BA , Komu M., Meoller HE, et al. Localized proton MR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study. Magn Reson Med1995; 33:589-594.
294.
Taylor-Robinson SD, Turjanski N., Bhattacharya S., et al. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metab Brain Dis1999; 14:45-55.
295.
Federico F. , Simone IL, Lucivero V., et al. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry1997 ; 62:239-242.
296.
Bowen BC, Block RE, Sanchez-Ramos J., et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol1995; 16:61-68.
297.
Tedeschi G. , Litvan I., Bonavita S., et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain1997; 120:1541-1552.
298.
Federico F. , Simone IL, Lucivero V., et al. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders . Move Disord1997; 12:903-909.
299.
Davie CA, Wenning GK, Barker GJ, et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol1995; 37:204-210.
300.
Davie CA, Wenning GK, Barker GJ, et al. MRS to differentiate multiple system atrophy from idiopathic Parkinson's disease. Lancet1993; 342:681-682.
301.
Clarke CE, Lowry M., Horsman A.Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov Disord1997; 12:297-301.
302.
Hu MT, Taylor-Robinson SD, Chaudhuri KR, et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31) P-MRS and (18) FDG-PET study. Brain2000; 123:340-352.
303.
Barbiroli B., Martinelli P., Patuelli A., et al. Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease . Mov Disord1999; 14:430-435.
304.
Ellis CM, Lemmens G., Williams Scr, et al. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology1997; 49:438-444.
305.
Cruz CJ, Aminoff MJ, Meyerhoff DJ, et al. Proton MR spectroscopic imaging in Parkinson's disease. Magn Reson Imaging1997; 15:619-624.
306.
Ray Chaudhuri K., Lemmens GM, Williams S., et al. Proton magnetic resonance spectroscopy of the striatum in Parkinson's disease patients with motor fluctuations. Parkinsonism Relat Disord1996; 2:63-67.
307.
Hoang TQ, Bluml S., Dubowitz DJ, et al. Quantitative proton-decoupled 31P MRS and 1 H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology1998; 50:1033-1040.
308.
O'Neill J., Schuff N., Marks WJ, et al. Proton magnetic resonance spectroscopy and volumetric MRI of the substantia nigra, basal ganglia, and association and motor cortices in idiopathic Parkinson's disease. Submitted.
309.
Davie CA, Barker GJ, Quinn N., et al. Proton MRS in Huntington's disease. Lancet1994; 343:1580.
310.
Jenkins BG , Koroshetz WJ, Beal MF, Rosen BREvidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology1993; 43:2689-2695.
311.
Koroshetz WJ, Jenkins BG, Rosen BR, Beal MFEnergy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol1997; 41:160-165.
312.
Jenkins BG , Rosas HD, Chen YC, et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology1998; 50:1357-1365.
313.
Taylor-Robinson SD, Weeks RA, Sargentoni J., et al. Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy. Lancet1994; 343:1170.
314.
Taylor-Robinson SD, Weeks RA, Bryant DJ, et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory . Mov Disord1996; 11:167-173.
315.
Kario K., Matsuo T., Hoshide S., et al. Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease: an MR spectroscopy study. Stroke1999; 30:1033-1037.
316.
Ricci PE Jr. Proton MR spectroscopy in ischemic stroke and other vascular disorders . Neuroimaging Clin N Am1998; 8:881-900.
317.
Kamei S., Oishi M., Takasu T.Evaluation of fasudil hydrochloride treatment for wandering symptoms in cerebrovascular dementia with 31P-magnetic resonance spectroscopy and Xecomputed tomography . Clin Neuropharmacol1996; 19:428-438.
